4.7 Article

CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer

Journal

MOLECULAR ONCOLOGY
Volume 2, Issue 4, Pages 327-339

Publisher

WILEY
DOI: 10.1016/j.molonc.2008.09.004

Keywords

Basal-like breast cancer; Genomic profiling; DNA amplification; Oncogene; Epithelial-mesenchymal transition; EMT

Categories

Funding

  1. NIH [CA112016]
  2. California Breast Cancer Research Program [8KB-0135, 11IB-0175]
  3. Norwegian Research Council
  4. NFR [155218/300]
  5. Korea Health 21 RD Project
  6. Ministry of Health Welfare R.O.K [01-PJ3-PG6-01GN07-0004]
  7. Norwegian Cancer Society
  8. sanofi-aventis Canada

Ask authors/readers for more resources

Breast cancer exhibits clinical and molecular heterogeneity, where expression profiling studies have identified five major molecular subtypes. The basal-like subtype, expressing basal epithelial markers and negative for estrogen receptor (ER), progesterone receptor (PR) and HER2, is associated with higher overall levels of DNA copy number alteration (CNA), specific CNAs bike gain on chromosome 10p), and poor prognosis. Discovering the molecular genetic basis of tumor subtypes may provide new opportunities for therapy. To identify the driver oncogene on 10p associated with basal-like tumors, we analyzed genomic profiles of 172 breast carcinomas. The smallest shared region of gain spanned just seven genes at 10p13, including calcium/calmodulin-dependent protein kinase 1D (CAMK1D), functioning in intracellular signaling but not previously linked to cancer. By microarray, CAMK1D was overexpressed when amplified, and by immunohistochemistry exhibited elevated expression in invasive carcinomas compared to carcinoma in situ. Engineered overexpression of CAMK1D in non-tumorigenic breast epithelial cells led to increased cell proliferation, and molecular and phenotypic alterations indicative of epithelial-mesenchymal transition (EMT), including loss of cell-cell adhesions and increased cell migration and invasion. Our findings identify CAMK1D as a novel amplified oncogene linked to EMT in breast cancer, and as a potential therapeutic target with particular relevance to clinically unfavorable basal-like tumors. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available